Polymorphisms of organic cation transporter 1 and the drugs response
Dyah Aryani Perwitasari(1*)
(1) 
(*) Corresponding Author
Abstract
Polymorphisms of proteins which have an important role in drug transport, metabolism, and disposition in the body
could affect the drugs efficacy and toxicity. The organic cation transporter 1 (OCT1), encoded by SLC22A1 gene,
has been known as one of the polyspecific protein transporters which could affect some of the cationic drug
response such as metformin, levodopa and imatinib. However, the findings of many studies an association of OCT1
polymorphisms and drug response both in Caucasian and Asian were still inconsistent. Moreover, this study’s topic
in Asians was still uncommon. This review was aimed to explore the polymorphisms of OCT 1 in Asians and Caucasians
and to find the challenges of the next studies in Asians. The articles about OCT1 polymorphisms were searched in
the PubMed with the keywords; OCT1 or SLC22A1, polymorphisms. There were ten articles of OCT1 polymorphisms
which are related to the drug response and most of the studies were performed in Caucasian subjects. In Caucasians,
the rs622342 variant might associated with the response of metformin and levodopa. Moreover, the R61C and
420del variants still showed the inconsistent findings associated with metformin response. The non-synonymous
variants which were found in Caucasians were not found in Asian. However, the new non-synonymous variants
were found in Japanese, Chinese, Indian and Korean population and some of them were associated with the metformin
response. The recent findings found in Caucasians cancer patients, were related to the association of non-synonymous
variants haplotype and the 5-Hydroxytriptamine Receptor Antagonists drug response. The inconsistent results of
OCT1 polymorphisms studies could be related to the study’s sample size and design of the studies. Further studies
which exploring the association of OCT1 polymorphisms and drug pharmacokinetic profiles and/or drug response,
which were adjusted by genetic variants of proteins involved in drug tansport, metabolism and disposition are still
needed in both Caucasians and Asians. Additional large studies also considering non-genetic risk factors are warranted,
to implement the results of the various studies into clinical practice.
Key words: OCT1- polymorphisms – Asians – Caucasians - drug response
could affect the drugs efficacy and toxicity. The organic cation transporter 1 (OCT1), encoded by SLC22A1 gene,
has been known as one of the polyspecific protein transporters which could affect some of the cationic drug
response such as metformin, levodopa and imatinib. However, the findings of many studies an association of OCT1
polymorphisms and drug response both in Caucasian and Asian were still inconsistent. Moreover, this study’s topic
in Asians was still uncommon. This review was aimed to explore the polymorphisms of OCT 1 in Asians and Caucasians
and to find the challenges of the next studies in Asians. The articles about OCT1 polymorphisms were searched in
the PubMed with the keywords; OCT1 or SLC22A1, polymorphisms. There were ten articles of OCT1 polymorphisms
which are related to the drug response and most of the studies were performed in Caucasian subjects. In Caucasians,
the rs622342 variant might associated with the response of metformin and levodopa. Moreover, the R61C and
420del variants still showed the inconsistent findings associated with metformin response. The non-synonymous
variants which were found in Caucasians were not found in Asian. However, the new non-synonymous variants
were found in Japanese, Chinese, Indian and Korean population and some of them were associated with the metformin
response. The recent findings found in Caucasians cancer patients, were related to the association of non-synonymous
variants haplotype and the 5-Hydroxytriptamine Receptor Antagonists drug response. The inconsistent results of
OCT1 polymorphisms studies could be related to the study’s sample size and design of the studies. Further studies
which exploring the association of OCT1 polymorphisms and drug pharmacokinetic profiles and/or drug response,
which were adjusted by genetic variants of proteins involved in drug tansport, metabolism and disposition are still
needed in both Caucasians and Asians. Additional large studies also considering non-genetic risk factors are warranted,
to implement the results of the various studies into clinical practice.
Key words: OCT1- polymorphisms – Asians – Caucasians - drug response
Full Text:
PDF (Bahasa Indonesia)Article Metrics
Abstract views : 780 | views : 1084Copyright (c) 2015 Dyah Aryani Perwitasari
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.